Abstract:Integrase strand transfer inhibitors (INSTIs) are the most recent class of antiretroviral drugs with potent and durable antiviral activity used to treat human immunodeficiency virus type 1 (HIV-1) infection. However, development of drug resistance increases the risk of treatment failure, disease progression and mortality. A better understanding of drug efficacy and resistance against INSTIs is crucial for their efficient use and the development of new antiretrovirals. A meta-analysis of studies reporting efficacy and resistance data on INSTI use in HIV-infected patients was performed. Odds ratios (ORs) of efficacy outcome data favouring INSTI use in different clinical settings demonstrated that INSTIs have higher efficacy compared with drugs of other classes. For combination antiretroviral therapy-naïve patients and virologically-suppressed patients who switched to INSTI-based therapy, the OR was 1.484 (95% CI 1.229-1.790) and 1.341 (95% CI 0.913-1.971), respectively. ORs of resistance data indicated decreased treatment-emergent resistance development to dolutegravir (DTG) upon virological failure than to non-INSTIs (OR = 0.081, 95% CI 0.004-1.849), whereas the opposite was observed for raltegravir (RAL) (OR = 3.137, 95% CI 1.827-5.385) and elvitegravir (EVG) (OR = 1.886, 95% CI 0.569-6.252). Pooled analysis of resistance data indicated that development of resistance to DTG and bictegravir was rare, whereas EVG and RAL had low genetic barriers to resistance and the intensive cross-resistance between them limits INSTI efficiency. Efficient means of monitoring the emergence of resistance to INSTIs and the development of drugs with high genetic barriers are clear paths for future research.

Research Progress in HIV Integrase Inhibitors

Research Progress of HIV-1 Integrase and Its Inhibitors

The Research Progress of anti-HIV Integrase Inhibitors

Progress in Research on HIV-1 Integrase and Its Inhibitors

Advances in Hiv-1 Integrase Inhibitors Directed Toward Different Steps of Integration

[Research Progress of Dual Inhibitors Targeting HIV-1 Reverse Transcriptase and Integrase].

Recent Advances Inn Small-Molecule Hiv-1 Inntegrase Inhibitors

Advances in the development of HIV integrase strand transfer inhibitors.

Meta-analysis and Systematic Review of the Efficacy and Resistance for Human Immunodeficiency Virus Type 1 Integrase Strand Transfer Inhibitors.

Progress of HIV-1 Integrase Inhibitors of Diketoacids

New developments in diketo-containing inhibitors of HIV-1 integrase.

A new antiretroviral agent against HIV:raltegravir

Inhibitors from Natural Products to HIV-1 Reverse Transcriptase, Protease and Integrase

Advances in the study of HIV-1 integrase inhibitors of alpha, gamma-diketo compounds]

Advances in the study of HIV-1 integrase inhibitors of α,γ-diketo compounds

Integrase inhibitors: current protagonists in antiretroviral therapy

Recent discoveries in HIV-1 reverse transcriptase inhibitors

HIV-1 Intergrase Inhibitors: 20032004 Update

Recent advances in clinical application of HIV-1 protease inhibitors

Design and Discovery of 5-Hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide Inhibitors of HIV-1 Integrase

Recent Progress in the Research of Small Molecule HIV-1 RNase H Inhibitors.